Literature DB >> 11701066

Analysis of risk factors predictive of distant failure after targeted chemoradiation for advanced head and neck cancer.

I Doweck1, K T Robbins, F Vieira.   

Abstract

BACKGROUND: Distant metastasis (DM) is the most common mode of recurrence among patients with advanced head and neck carcinoma treated with intra-arterial cisplatin and radiotherapy (RADPLAT).
OBJECTIVE: To identify which patients are at greatest risk for DM and would benefit the most from new strategies designed to treat occult metastases.
METHODS: Between 1993 and 1999, 250 patients with advanced head and neck cancer were treated by RADPLAT. Excluded from the analysis were 10 patients who either did not complete the protocol or were unavailable for follow-up and 39 patients with persistent disease or local recurrence. The incidence and the risk factors for DM in these patients were evaluated in a model that included the following factors: age, T and N classification, site of tumor, histologic grade, number (0, 1, or >1) and position (high vs low) of neck levels involved, and bilateral nodal disease. Multiple stepwise logistic regression was used for the analysis.
RESULTS: In a univariate analysis, the following variables correlated to DM: N classification (P =.02), site of tumor (P =.01), lower neck nodes (P =.002), number of neck levels involved (P =.001), and bilateral nodal disease (P =.02). In a multivariate analysis, the most significant risk factors for DM were the number of neck levels involved and the site of the primary tumor (P<.001). The highest odds ratios for DM were among patients with multiple levels of nodal involvement (3.17) and patients with hypopharyngeal carcinoma (2.8).
CONCLUSIONS: Patients with more than 1 level of clinical nodal involvement and patients with hypopharyngeal carcinoma have the highest risk of developing DM as the initial site of failure and would benefit most from treatment strategies that address occult distant disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11701066     DOI: 10.1001/archotol.127.11.1315

Source DB:  PubMed          Journal:  Arch Otolaryngol Head Neck Surg        ISSN: 0886-4470


  5 in total

1.  Heparanase localization and expression by head and neck cancer: correlation with tumor progression and patient survival.

Authors:  Ilana Doweck; Victoria Kaplan-Cohen; Inna Naroditsky; Edmond Sabo; Neta Ilan; Israel Vlodavsky
Journal:  Neoplasia       Date:  2006-12       Impact factor: 5.715

2.  Clinical nodal stage is an independently significant predictor of distant failure in patients with squamous cell carcinoma of the larynx.

Authors:  Jeannette Marie S Matsuo; Snehal G Patel; Bhuvanesh Singh; Richard J Wong; Jay O Boyle; Dennis H Kraus; Ashok R Shaha; Michael J Zelefsky; David G Pfister; Jatin P Shah
Journal:  Ann Surg       Date:  2003-09       Impact factor: 12.969

3.  Concurrent intra-arterial carboplatin administration and radiation therapy for the treatment of advanced head and neck squamous cell carcinoma: short term results.

Authors:  Giulia Bertino; Antonio Occhini; Carlo Emilio Falco; Camillo Porta; Franco Corbella; Sara Colombo; Vittoria Balcet; Patrizia Morbini; Federico Zappoli; Andrea Azzaretti; Giuseppe Rodolico; Carmine Tinelli; Marco Benazzo
Journal:  BMC Cancer       Date:  2009-09-04       Impact factor: 4.430

4.  Intra-arterial chemoradiation for T3-4 oral cavity cancer: treatment outcomes in comparison to oropharyngeal and hypopharyngeal carcinoma.

Authors:  Ilana Doweck; K Thomas Robbins; Sandeep Samant; Francisco Vieira
Journal:  World J Surg Oncol       Date:  2008-01-14       Impact factor: 2.754

5.  A multicenter phase II trial of paclitaxel, carboplatin, and cetuximab followed by chemoradiotherapy in patients with unresectable locally advanced squamous cell carcinoma of the head and neck.

Authors:  Tomohiro Enokida; Takenori Ogawa; Akihiro Homma; Kenji Okami; Shujiro Minami; Ayako Nakanome; Yasushi Shimizu; Daisuke Maki; Yuri Ueda; Takao Fujisawa; Atsushi Motegi; Akira Ohkoshi; Jun Taguchi; Koji Ebisumoto; Shogo Nomura; Susumu Okano; Makoto Tahara
Journal:  Cancer Med       Date:  2020-01-13       Impact factor: 4.452

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.